DexCom, Inc. (NASDAQ:DXCM) Holdings Raised by Zions Bancorporation N.A.

Zions Bancorporation N.A. grew its position in DexCom, Inc. (NASDAQ:DXCMGet Rating) by 61.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,684 shares of the medical device company’s stock after acquiring an additional 1,025 shares during the quarter. Zions Bancorporation N.A.’s holdings in DexCom were worth $1,373,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the company. American National Bank increased its holdings in shares of DexCom by 33.8% in the 1st quarter. American National Bank now owns 91 shares of the medical device company’s stock valued at $47,000 after acquiring an additional 23 shares during the last quarter. O Shaughnessy Asset Management LLC increased its holdings in shares of DexCom by 1.8% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 1,384 shares of the medical device company’s stock valued at $743,000 after acquiring an additional 25 shares during the last quarter. DAVENPORT & Co LLC increased its holdings in shares of DexCom by 1.9% in the 4th quarter. DAVENPORT & Co LLC now owns 1,383 shares of the medical device company’s stock valued at $743,000 after acquiring an additional 26 shares during the last quarter. Parkside Financial Bank & Trust grew its stake in DexCom by 27.0% during the 4th quarter. Parkside Financial Bank & Trust now owns 141 shares of the medical device company’s stock worth $75,000 after buying an additional 30 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. grew its stake in DexCom by 2.9% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 1,120 shares of the medical device company’s stock worth $573,000 after buying an additional 32 shares during the last quarter. 92.34% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Steven Robert Pacelli sold 1,000 shares of the company’s stock in a transaction on Monday, July 25th. The stock was sold at an average price of $83.07, for a total value of $83,070.00. Following the completion of the sale, the director now owns 138,700 shares in the company, valued at $11,521,809. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 3,000 shares of company stock worth $239,830 over the last 90 days. 0.41% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research analysts recently commented on DXCM shares. Citigroup lowered their price objective on DexCom from $105.00 to $100.00 in a research note on Friday, July 29th. Oppenheimer lowered their price objective on DexCom from $131.00 to $105.00 in a research note on Friday, July 29th. Piper Sandler lowered their price objective on DexCom from $120.00 to $110.00 and set an “overweight” rating for the company in a research note on Friday, July 29th. Robert W. Baird lowered their price objective on DexCom from $115.00 to $97.00 in a research note on Friday, July 29th. Finally, Wells Fargo & Company lowered their price objective on DexCom from $144.00 to $102.00 in a research note on Friday, July 29th. Two equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $115.23.

DexCom Trading Up 3.6 %

Shares of DexCom stock opened at $91.59 on Friday. The company has a quick ratio of 4.30, a current ratio of 4.72 and a debt-to-equity ratio of 0.87. The firm has a market cap of $35.96 billion, a price-to-earnings ratio of 190.82, a price-to-earnings-growth ratio of 3.32 and a beta of 1.03. The business has a fifty day simple moving average of $84.10 and a 200-day simple moving average of $92.43. DexCom, Inc. has a fifty-two week low of $66.89 and a fifty-two week high of $164.86.

DexCom (NASDAQ:DXCMGet Rating) last announced its quarterly earnings data on Thursday, July 28th. The medical device company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.02). The firm had revenue of $696.20 million during the quarter, compared to analyst estimates of $709.33 million. DexCom had a net margin of 7.47% and a return on equity of 11.79%. The company’s quarterly revenue was up 17.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.19 EPS. On average, equities analysts forecast that DexCom, Inc. will post 0.79 EPS for the current fiscal year.

DexCom Profile

(Get Rating)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.

Read More

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.